Hydroxyurea (HU) is now widely used in the treatment of sickle cell disease (SCD). The effect of this agent on T-lymphocytes in this disease has not been extensively studied. In other diseases such as human immunodeficiency virus (HIV) disease, HU was found to have a variable effect on T-cell subsets. We previously reported (

Blood 2002; 100: 363
) a case of a sickle cell disease patient who was HIV- negative who was found to have low CD4 count on HU that normalized after stopping this agent. We have since conducted a case-controlled study in our sickle cell disease clinic in an attempt to analyze the effects of HU on CD4 count and other T-lymphocyte subsets. Written informed consent was obtained from 15 SCD patients. All patients had SCD as confirmed by hemoglobin electrophoresis. We placed patients into 2 cohorts: the treatment group consisted of patients already receiving HU therapy and the control group consisted of patients not taking HU. Among 15 patients, 8 patients were in treatment group and 7 patients were in the control group. In control group, 5 patients were female and 2 patients were male with mean age of 38 years. In treatment group, 7 patients were female and 1 was male with mean age of 35 years. In the treatment group, the mean duration of HU therapy was 4 years. We collected venous blood from all patients and tested for the following blood cell counts: total white blood cell (WBC), total neutrophil, total lymphocyte, CD4, CD8, CD3 cells and CD4/CD8 ratio. We also tested and found that there was no significant difference between the 2 cohorts for the presence of alloantibodies, cytomegalovirus virus and hepatitis C viral status. All patients were found to be HIV- negative. The lymphocyte assay was done using Coulter MAXAM hematology analyzer and using a combination of white blood cell counts and differential count in the same laboratory for all patients. We compared the mean value of total T-lymphocyte counts, T-cell subgroups CD4, CD8, CD3 levels and CD4/CD8 ratios between the 2 groups by performing the t-test (Table 1). Our study showed that the treatment group had a statistically significant increase in total T- lymphocyte count and in levels of the CD4, CD8 and CD3 levels compared to the control group. There was no difference in the CD4/CD8 ratio between the 2 groups. These results provide additional information to our previous observation of a lowered CD4 count in a SCD patient on HU. These results are consistent with findings in HIV positive patients where changes in T- lymphocytes subsets have been observed in patients treated with HU (
AIDS 2002; 14:619–621
and
J Acquir Immune Defic Syndr 2000; 25: 329–336
). We conclude that in SCD patients HU can affect T-lymphocyte subset counts. The mechanism and clinical significance of the effect, if any, is unknown and requires further investigation.

Table 1: Effects of HU on T-lymphocytes

Blood testControl grouptreatment groupP value
* P-value significant below 0.05 
Total WBC th/mm3 15.36 12.28 0.23 
Neutrophil ct/mm3 7.87 4.92 0.12 
Total lymphocyte ct/mm3 2458.83 3739.4 0.01* 
Absolute CD4, mm3 1621.7 2284.8 0.05* 
Absolute CD8, mm3 701.42 1340.33 0.01* 
Absolute CD3, mm3 2520 3723 0.01* 
CD4/CD8 Ratio 2.321 2.32 0.99 
Blood testControl grouptreatment groupP value
* P-value significant below 0.05 
Total WBC th/mm3 15.36 12.28 0.23 
Neutrophil ct/mm3 7.87 4.92 0.12 
Total lymphocyte ct/mm3 2458.83 3739.4 0.01* 
Absolute CD4, mm3 1621.7 2284.8 0.05* 
Absolute CD8, mm3 701.42 1340.33 0.01* 
Absolute CD3, mm3 2520 3723 0.01* 
CD4/CD8 Ratio 2.321 2.32 0.99 
View Large

Topics:
hydroxyurea, sickle cell anemia, t-lymphocyte subsets, acquired immunodeficiency syndrome, blood tests, hemoglobin electrophoresis, hepatitis c, hiv seropositivity, isoantibodies, cd4 count determination procedure

Author notes

Corresponding author

2005, The American Society of Hematology
2004
Sign in via your Institution